Starpharma Holdings (SPHRF) 0.5063 $SPHRF
Australian Olympic Team Taking Dual Protect(TM) VivaGel(R) Condoms to Rio
BusinessWire - Sun May 15, 11:32PM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) and Ansell Limited (ASX:ANN) today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect(TM) VivaGel(R) condoms for the upcoming Olympic Games in Rio de Janeiro.
ANN: 44.89 (-0.16)
VivaGel Active against Zika Virus
BusinessWire - Thu May 05, 7:15PM CDT
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that the VivaGel(R) active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel(R) condom.
Viral Conjunctivitis Pipeline Review, H1 2016 Featuring Adenovir Pharma, NanoViricides, Panoptes Pharma Ges.m.b.H. , Shire & Starpharma Holdings Limited - Research and Markets
BusinessWire - Wed Apr 13, 5:54AM CDT
Research and Markets has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H1 2016" report to their offering.
Viral Conjunctivitis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n8rw5v/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Viral Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug Profiles - APD-209 - astodrimer - EKCCide-I - FST-100 - PP-001 - Trisialic Acid Companies Mentioned - Adenovir Pharma AB - NanoViricides, Inc. - Panoptes Pharma Ges.m.b.H. - Shire Plc - Starpharma Holdings Limited For more information visit http://www.researchandmarkets.com/research/n8rw5v/viral
SHPG: 199.82 (+1.22), NNVC: 1.67 (-0.04)
Global Genital Herpes Pipeline Review 2015 - 19 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqbrzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Admedus Ltd - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - PaxVax - Profectus BioSciences, Inc. - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS - Vaxart, Inc. - Vical Incorporated Drug Profiles - acyclovir - Aspidasept - astodrimer - G-103 - GEN-002 - GEN-003 - genital herpes vaccine [HSV-2] - GV-2207 - HerpeCide-I - herpes simplex virus [serotype 2] vaccine - herpes simplex virus [type 1, 2] vaccine - HSV-529 - pritelivir - SB-105A10 - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/hq...tal_herpes
VICL: 4.22 (-0.05), IMDZ: 6.84 (-0.20), FOMX: 8.70 (-0.03), GNCA: 5.18 (-0.05), NNVC: 1.67 (-0.04)
OTCQX Life Sciences Presentation
PR Newswire - Tue Sep 29, 7:47AM CDT
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday, October 1, 2015 at 12.15pm (EDT time). The presentation is part of a special OTCQX Life Sciences virtual Conference.
ANN: 44.89 (-0.16)
Bacterial Vaginosis - Pipeline Review, H2 2015
M2 - Fri Sep 04, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pq3lrc/bacterial) has announced the addition of the "Bacterial Vaginosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Alfa Wassermann - AmVac - Osel - Starpharma Holdings - Symbiomix Therapeutics For more information visit http://www.researchandmarkets.com/research/pq3lrc/bacterial
Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 6.84 (-0.20), CVM: 0.53 (+0.02), FOMX: 8.70 (-0.03), ADMP: 2.65 (-0.01), GNCA: 5.18 (-0.05), NNVC: 1.67 (-0.04), CMRX: 4.31 (-0.05)
Starpharma Holdings Limited - Product Pipeline Review - 2014
M2 - Wed Jun 10, 3:25AM CDT
Product Pipeline Review - 2014
Viral Conjunctivitis Pipeline Review, H1 2015 - 5 Companies & 7 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22rgnh/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Viral Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Foresight Biotherapeutics, Inc. - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Panoptes Pharma Ges.m.b.H. - Starpharma Holdings Limited Drug Profiles - astodrimer - EKCCide-I - FST-100 - NVC-638 - NVC-704 - NVC-727 - PP-001 For more information visit http://www.researchandmarkets.com/research/22rgnh/viral
NNVC: 1.67 (-0.04)
Genital Herpes Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k7sxzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agenus, Inc. - AiCuris GmbH & Co. KG - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Vical Incorporated Drug Profiles - acyclovir - astodrimer - GEN-003 - genital herpes vaccine - genital herpes vaccine [HSV-2] - HerpeCide-I - herpes simplex vaccine - HSV [type 2] vaccine - pritelivir - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/k7...tal_herpes
VICL: 4.22 (-0.05), FOMX: 8.70 (-0.03), GNCA: 5.18 (-0.05), NNVC: 1.67 (-0.04)
Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" on February 14, 2015
Marketwired - Fri Feb 13, 6:15AM CST
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio's Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel(R), the company's development of the world's first antiviral condom (the VivaGel(R) condom) which was recently launched in Australia by Starpharma's partner, Ansell. Dr Fairley will also talk about Starpharma's current US Phase III clinical trials of VivaGel(R) for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company's improved version of cancer drug docetaxel (Taxotere). The Company's product, DEP(TM) docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP(TM) docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere(R) and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup(R)) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
ANN: 44.89 (-0.16)
Human Papillomavirus Infections - Pipeline Review, H2 2014
M2 - Fri Dec 19, 4:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/8sdzln/human) has announced the addition of the "Human Papillomavirus Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Agilvax - Beijing Minhai Biotechnology - Bharat Biotech International - Chong Kun Dang Pharmaceutical - Chongqing Zhifei Biological Products - Crucell - FluGen - Genticel - Immunservice - Indian Immunologicals - MediGene - Merck & Co - Nielsen Biosciences - Redbiotec - Selecta Biosciences - Shanghai Zerun Biotechnology - Spider Biotech - Starpharma Holdings - Takeda Pharmaceutical - Vaxart For more information visit http://www.researchandmarkets.com/research/8sdzln/human
MRK: 63.36 (-0.27)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 4.22 (-0.05), NNVC: 1.67 (-0.04)
Nanotechnology - 2014 Global Strategic Business Report
M2 - Thu Oct 23, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6n85z6/nanotechnology) has announced the addition of the "Nanotechnology - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 411 companies including many key and niche players. This report analyzes the worldwide markets for Nanotechnology in US$ Billion by the following End-Use Sectors: - Chemicals - Automotive - Aerospace & Defense - Semiconductors & Electronics - Pharma & Healthcare - Food - Others Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Review Of Select Nanotechnology Based Product Markets 3. R&D Structure & Financing 4. Nanotech Patents - An Overview 5. Technology Overview 6. Techniques And Technologies 7. Nanotech Fears - Are They Justified? 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 411 (including Divisions/Subsidiaries - 424) - The United States (208) - Canada (11) - Japan (37) - Europe (131) - - France (7) - - Germany (54) - - The United Kingdom (28) - - Italy (3) - - Spain (1) - - Rest of Europe (38) - Asia-Pacific (Excluding Japan) (29) - Middle East (
Companies Mentioned - Advanced Diamond Technologies, Inc. - Advanced Nano Products Co., Limited - Altair Nanotechnologies Inc. - Arrowhead Research Corporation - Bruker Corporation - Catalytic Materials, LLC - Chemat Technology Inc. - eSpin Technologies, Inc. - ELITech Group - Genefluidics, Inc., - Hanwha Nanotech Corporation - Hybrid Plastics - Hyperion Catalysis International, Inc. - Integran Technologies, Inc. - Intrinsiq Materials Limited - Life Technologies Corporation - Luxtera, Inc. - Nanocyl S.A. - NanoMaterials Ltd, - Nanosys, Inc. - QuantumSphere, Inc. - Raymor Industries, Inc. - Rogue Valley Microdevices, Inc. - Shenzhen Nanotech Port Co., Ltd. - SouthWest NanoTechnologies, Inc. - Starpharma Holdings - Teledyne Scientific & Imaging, LLC - Unidym, Inc. For more information visit http://www.researchandmarkets.com/research/6n...technology
LIFE: 3.34 (-0.03), ARWR: 7.50 (+0.44)
Australian Olympic Team Taking Dual Protect(TM) VivaGel(R) Condoms to Rio
BusinessWire - Sun May 15, 11:32PM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) and Ansell Limited (ASX:ANN) today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect(TM) VivaGel(R) condoms for the upcoming Olympic Games in Rio de Janeiro.
ANN: 44.89 (-0.16)
VivaGel Active against Zika Virus
BusinessWire - Thu May 05, 7:15PM CDT
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that the VivaGel(R) active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel(R) condom.
Viral Conjunctivitis Pipeline Review, H1 2016 Featuring Adenovir Pharma, NanoViricides, Panoptes Pharma Ges.m.b.H. , Shire & Starpharma Holdings Limited - Research and Markets
BusinessWire - Wed Apr 13, 5:54AM CDT
Research and Markets has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H1 2016" report to their offering.
Viral Conjunctivitis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n8rw5v/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Viral Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug Profiles - APD-209 - astodrimer - EKCCide-I - FST-100 - PP-001 - Trisialic Acid Companies Mentioned - Adenovir Pharma AB - NanoViricides, Inc. - Panoptes Pharma Ges.m.b.H. - Shire Plc - Starpharma Holdings Limited For more information visit http://www.researchandmarkets.com/research/n8rw5v/viral
SHPG: 199.82 (+1.22), NNVC: 1.67 (-0.04)
Global Genital Herpes Pipeline Review 2015 - 19 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqbrzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Admedus Ltd - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - PaxVax - Profectus BioSciences, Inc. - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS - Vaxart, Inc. - Vical Incorporated Drug Profiles - acyclovir - Aspidasept - astodrimer - G-103 - GEN-002 - GEN-003 - genital herpes vaccine [HSV-2] - GV-2207 - HerpeCide-I - herpes simplex virus [serotype 2] vaccine - herpes simplex virus [type 1, 2] vaccine - HSV-529 - pritelivir - SB-105A10 - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/hq...tal_herpes
VICL: 4.22 (-0.05), IMDZ: 6.84 (-0.20), FOMX: 8.70 (-0.03), GNCA: 5.18 (-0.05), NNVC: 1.67 (-0.04)
OTCQX Life Sciences Presentation
PR Newswire - Tue Sep 29, 7:47AM CDT
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday, October 1, 2015 at 12.15pm (EDT time). The presentation is part of a special OTCQX Life Sciences virtual Conference.
ANN: 44.89 (-0.16)
Bacterial Vaginosis - Pipeline Review, H2 2015
M2 - Fri Sep 04, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pq3lrc/bacterial) has announced the addition of the "Bacterial Vaginosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Alfa Wassermann - AmVac - Osel - Starpharma Holdings - Symbiomix Therapeutics For more information visit http://www.researchandmarkets.com/research/pq3lrc/bacterial
Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 6.84 (-0.20), CVM: 0.53 (+0.02), FOMX: 8.70 (-0.03), ADMP: 2.65 (-0.01), GNCA: 5.18 (-0.05), NNVC: 1.67 (-0.04), CMRX: 4.31 (-0.05)
Starpharma Holdings Limited - Product Pipeline Review - 2014
M2 - Wed Jun 10, 3:25AM CDT
Product Pipeline Review - 2014
Viral Conjunctivitis Pipeline Review, H1 2015 - 5 Companies & 7 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22rgnh/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Viral Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Foresight Biotherapeutics, Inc. - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Panoptes Pharma Ges.m.b.H. - Starpharma Holdings Limited Drug Profiles - astodrimer - EKCCide-I - FST-100 - NVC-638 - NVC-704 - NVC-727 - PP-001 For more information visit http://www.researchandmarkets.com/research/22rgnh/viral
NNVC: 1.67 (-0.04)
Genital Herpes Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k7sxzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agenus, Inc. - AiCuris GmbH & Co. KG - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Vical Incorporated Drug Profiles - acyclovir - astodrimer - GEN-003 - genital herpes vaccine - genital herpes vaccine [HSV-2] - HerpeCide-I - herpes simplex vaccine - HSV [type 2] vaccine - pritelivir - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/k7...tal_herpes
VICL: 4.22 (-0.05), FOMX: 8.70 (-0.03), GNCA: 5.18 (-0.05), NNVC: 1.67 (-0.04)
Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" on February 14, 2015
Marketwired - Fri Feb 13, 6:15AM CST
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio's Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel(R), the company's development of the world's first antiviral condom (the VivaGel(R) condom) which was recently launched in Australia by Starpharma's partner, Ansell. Dr Fairley will also talk about Starpharma's current US Phase III clinical trials of VivaGel(R) for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company's improved version of cancer drug docetaxel (Taxotere). The Company's product, DEP(TM) docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP(TM) docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere(R) and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup(R)) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
ANN: 44.89 (-0.16)
Human Papillomavirus Infections - Pipeline Review, H2 2014
M2 - Fri Dec 19, 4:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/8sdzln/human) has announced the addition of the "Human Papillomavirus Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Agilvax - Beijing Minhai Biotechnology - Bharat Biotech International - Chong Kun Dang Pharmaceutical - Chongqing Zhifei Biological Products - Crucell - FluGen - Genticel - Immunservice - Indian Immunologicals - MediGene - Merck & Co - Nielsen Biosciences - Redbiotec - Selecta Biosciences - Shanghai Zerun Biotechnology - Spider Biotech - Starpharma Holdings - Takeda Pharmaceutical - Vaxart For more information visit http://www.researchandmarkets.com/research/8sdzln/human
MRK: 63.36 (-0.27)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 4.22 (-0.05), NNVC: 1.67 (-0.04)
Nanotechnology - 2014 Global Strategic Business Report
M2 - Thu Oct 23, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6n85z6/nanotechnology) has announced the addition of the "Nanotechnology - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 411 companies including many key and niche players. This report analyzes the worldwide markets for Nanotechnology in US$ Billion by the following End-Use Sectors: - Chemicals - Automotive - Aerospace & Defense - Semiconductors & Electronics - Pharma & Healthcare - Food - Others Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Review Of Select Nanotechnology Based Product Markets 3. R&D Structure & Financing 4. Nanotech Patents - An Overview 5. Technology Overview 6. Techniques And Technologies 7. Nanotech Fears - Are They Justified? 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 411 (including Divisions/Subsidiaries - 424) - The United States (208) - Canada (11) - Japan (37) - Europe (131) - - France (7) - - Germany (54) - - The United Kingdom (28) - - Italy (3) - - Spain (1) - - Rest of Europe (38) - Asia-Pacific (Excluding Japan) (29) - Middle East (
Companies Mentioned - Advanced Diamond Technologies, Inc. - Advanced Nano Products Co., Limited - Altair Nanotechnologies Inc. - Arrowhead Research Corporation - Bruker Corporation - Catalytic Materials, LLC - Chemat Technology Inc. - eSpin Technologies, Inc. - ELITech Group - Genefluidics, Inc., - Hanwha Nanotech Corporation - Hybrid Plastics - Hyperion Catalysis International, Inc. - Integran Technologies, Inc. - Intrinsiq Materials Limited - Life Technologies Corporation - Luxtera, Inc. - Nanocyl S.A. - NanoMaterials Ltd, - Nanosys, Inc. - QuantumSphere, Inc. - Raymor Industries, Inc. - Rogue Valley Microdevices, Inc. - Shenzhen Nanotech Port Co., Ltd. - SouthWest NanoTechnologies, Inc. - Starpharma Holdings - Teledyne Scientific & Imaging, LLC - Unidym, Inc. For more information visit http://www.researchandmarkets.com/research/6n...technology LIFE: 3.34 (-0.03), ARWR: 7.50 (+0.44)
